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ABSTRACT 23 
Bovine colostrum (COL) has been advocated as a nutritional countermeasure to 24 
exercise-induced immune dysfunction and increased risk of upper respiratory illness 25 
(URI) in athletic populations, however, the mechanisms remain unclear. During winter 26 
months, under double-blind procedures, 53 males (mean training load ± SD, 50.5 ± 27 
28.9 MET-hweek-1) were randomized to daily supplementation of 20 g of COL (N = 28 
25) or an isoenergetic/isomacronutrient placebo (PLA) (N = 28) for 12 weeks. Venous 29 
blood was collected at baseline and at 12 weeks and unstimulated saliva samples at 30 
4-week intervals.  There was a significantly lower proportion of URI days and number 31 
of URI episodes with COL compared to PLA over the 12 weeks (p < 0.05). There was 32 
no effect of COL on in vitro neutrophil oxidative burst, salivary secretory IgA or salivary 33 
antimicrobial peptides (p > 0.05), which does not support previously suggested 34 
mechanisms. In a subset of participants (COL = 14, PLA = 17), real-time quantitative 35 
PCR, targeting the 16S rRNA gene showed there was an increase in salivary bacterial 36 
load over the 12-week period with PLA (p < 0.05) which was not as evident with COL. 37 
Discriminant function analysis of outputs received from serum metabolomics showed 38 
changes across time but not between groups. This is the first study to demonstrate 39 
that COL limits the increased salivary bacterial load in physically active males during 40 
the winter months which may provide a novel mechanism of immune-modulation with 41 
COL and a relevant marker of in vivo (innate) immunity and risk of URI. 42 
Keywords: URTI, innate immunity, mucosal immunity, microbiome, 16S rRNA, 43 
metabolomics 44 
  45 
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1. Introduction 46 
It is now well established that exercise of a strenuous and/or prolonged nature can 47 
lead to significant transient perturbations of immune function (commonly referred to as 48 
immunodepression) which includes, but is not limited to, decreases in both cell-49 
mediated and mucosal parameters (Nieman, 2007). This may result in an ‘open 50 
window’ during which risk of illness is increased (Nieman, 2000). Hence, if such 51 
exercise is performed on a regular basis, as with endurance athletes, and particularly 52 
in combination with other life stressors (e.g. inadequate nutrition, psychological stress) 53 
the overall risk can be substantially higher (Gleeson, 2007).  The increase in the 54 
frequency and severity of symptoms of upper respiratory illness (URI) in athletes (e.g. 55 
sore throat, runny nose) has been attributed to such periods of heavy exertion (Walsh 56 
et al., 2011). 57 
Bovine colostrum (COL) may be effective at alleviating recurrent URI in situations of 58 
immune deficiency (Patel and Rana, 2006). Previous evidence has shown that 8-10 59 
weeks of COL supplementation can reduce the incidence of URI in physically active 60 
populations but the mechanism(s) behind such effects remains unclear (Brinkworth 61 
and Buckley, 2003; Crooks et al., 2010). Animal and in-vitro culture studies 62 
demonstrate that COL has a mediating effect on cell-mediated immunity by influencing 63 
the production of cytokines (Biswas et al., 2007; Boudry et al., 2007; Shing et al., 64 
2009). Increasing concentrations of COL, in-vitro, has been shown to modulate 65 
cytokine production in peripheral blood mononuclear cells from resting, healthy 66 
individuals, to promote a  Th1 profile (cell-mediated immunity) (Shing et al., 2009), 67 
which may suppress the binding of pathogens (e.g. rhinovirus) (Sethi et al., 1997). 68 
Direct effects of COL on leukocyte capacity are also supported by evidence of an 69 
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enhancement of phagocytosis and oxidative burst of polymorphonuclear cells (i.e. 70 
neutrophils) following short term culture with COL (Sugisawa et al., 2001, 2002, 2003). 71 
Sugisawa et al. (2003) proposed that in the presence of COL leukocytes become 72 
primed for subsequent activation by low-molecular weight substances (< 10 kDa) such 73 
as protease peptones. 74 
Given the aforementioned effects of COL within inflammatory in vitro culture 75 
conditions, it may be expected that COL can act as a nutritional countermeasure to 76 
exercise-induced immunodepression. Our previous work suggests that 4 weeks of 77 
COL (20 gday-1) supplementation can limit the immunodepressive effects of an acute 78 
physical stressor (2 h of cycling) by enhancing neutrophil function (stimulated 79 
degranulation/elastase release) post-exercise (Davison and Diment, 2010). Within this 80 
study the modulatory effects of COL also extended to innate mucosal immunity by 81 
preventing the exercise-induced decrease of salivary lysozyme concentration and 82 
secretion.  83 
Such findings may provide support to proposed mechanisms that some of the immune-84 
modulatory effects of COL are due to bioactive components that become biologically 85 
available upon digestion of COL and prime leukocyte capacity (Davison, 2013). It is 86 
currently unclear whether longer term supplementation of COL and exposure to these 87 
priming agents also leads to changes in innate markers in athletes at rest. Crooks et 88 
al. (2006) demonstrated that longer periods of COL supplementation (i.e. 12 weeks) 89 
may be associated with significant increases in resting concentrations of salivary 90 
secretory IgA (sIgA), which is the only immune measure to date that has been 91 
consistently related to risk of URI in exercising populations (Walsh et al., 2011). Other 92 
studies have also seen improvements in resting sIgA concentrations with COL 93 
supplementation but have not monitored URI (Appukutty et al., 2010; Mero et al., 94 
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2002). To date, the majority of both longitudinal and cross-sectional exercise training 95 
studies have focused on changes in salivary sIgA (Walsh et al., 2011).  Although the 96 
importance of other salivary antimicrobial peptides (AMPs) (e.g. lysozyme, lactoferrin) 97 
for host defense have been recognized, they have received limited attention (West et 98 
al., 2006).  99 
In addition to the presence of inducible factors such as AMPs at mucosal surfaces, 100 
protection from invading microorganisms is also provided by the diverse community of 101 
commensal microbes which colonize the upper respiratory tract (Blaser and Falkow, 102 
2009; Bosch et al., 2013).  Subsequently, disturbance of this respiratory microbial 103 
community can contribute to acquisition of new pathogens which may result in 104 
respiratory illness, particularly if host immunity is compromised (Murphy et al., 2009). 105 
However, the effects of exercise and nutritional interventions on changes in the 106 
salivary microbiome have not previously been investigated.  107 
The aims of this study were to investigate the effects of 12 weeks of COL 108 
supplementation on innate and mucosal immunity as well as the salivary microbiome 109 
in a population of males who engage in exercise training during the winter months. 110 
The study also aimed to determine whether any effects of COL on these parameters 111 
would also lead to a change in the incidence of URI. Given the potential involvement 112 
of a diverse array of biological pathways, we also undertook a metabolomic profiling 113 
approach on serum in an attempt to gain a more detailed understanding of any 114 
modulation of the immune system by COL.  115 
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2. Methods 116 
2.1. Participants 117 
Following both verbal and written details of the procedures, 57 male participants 118 
provided written informed consent for their inclusion within the study. The study was 119 
conducted in accordance with the Declaration of Helsinki principles and all procedures 120 
were approved by the Research Ethics Committee of Aberystwyth University. 121 
Participants were non-smokers, not taking medication or other supplements, free from 122 
any infectious illness for 4 weeks prior to the study and completing at least 3 h of 123 
moderate-vigorous endurance exercise per week. Participants were not limited in their 124 
use of mouthwash before and during the study period. 125 
2.2. Supplementation 126 
All 57 participants were randomly allocated into COL or placebo (PLA) groups with 127 
stratification by age and type of exercise training only. In a double blind manner, 128 
participants were asked to consume 20 gday-1 (10 g prior to morning and evening 129 
meal) of COL (Neovite UK, London) or an isoenergetic/isomacronutrient PLA (as used 130 
in Davison and Diment, 2010) for 12 weeks. Four participants (COL = 3, PLA = 1) were 131 
lost due to lack of compliance with the study protocol (e.g. lack of training or 132 
supplement consumption due to injury, family bereavement or air travel). All 133 
participants who successfully completed the study (COL group, n = 25, age: 30.5 ± 134 
13.8 years, height: 179.9 ± 6.4 cm, body mass: 77.2 ± 8.9 kg); PLA group, n = 28, age: 135 
31.5 ± 13.2 years, height 178.4 ± 6.6 cm, body mass 74.5 ± 8.7 kg) commenced the 136 
study between September and December. 137 
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2.3. Monitoring of upper respiratory illness and training volume 138 
Participants completed a health questionnaire (Gleeson et al., 2011, 2012) on a daily 139 
basis. This involved participants indicating if they were suffering from any of the illness 140 
symptoms listed on the questionnaire: sore throat, catarrh in the throat, runny nose, 141 
cough, repetitive sneezing, fever, persistent muscle soreness, joint aches and pains, 142 
weakness, headache, and loss of sleep. Upon reporting of any of the above 143 
symptoms, participants were asked to provide a subjective rating of the severity of 144 
symptoms (light, moderate, severe). As used previously (Fricker et al., 2005; Gleeson 145 
et al., 2011, 2012), these ratings of light, moderate and severe were given numerical 146 
scores of 1, 2 and 3 respectively for data analysis. At any given point during the 12 147 
weeks, a total symptom score of ≥12 was used to indicate that an URI was present.  148 
Each week, participants were  asked to complete a standard short-form International 149 
Physical Activity Questionnaire (http://www.ipaq.ki.se/downloads.htm) to provide 150 
quantitative data of training loads in metabolic-equivalent (MET)-hweek-1 (Craig et al., 151 
2003). Participants were allowed unrestricted use of medication during episodes of 152 
URI but were asked to report such use and report how their training was affected by 153 
the URI (1 – training maintained, 2- training reduced, 3 – training discontinued).      154 
2.4. Blood sampling 155 
Blood samples were drawn from an antecubital vein into 4 ml K3EDTA (BD, Oxford, 156 
UK) and 6 ml plain (BD, Oxford, UK) vacutainers at baseline and 12 weeks following 157 
COL or PLA supplementation.  All participants avoided strenuous exercise for 24 h 158 
prior to each visit and arrived at the laboratory following an overnight fast of at least 159 
10 h. Blood collected in the K3EDTA vacutainer was used for determination of total 160 
and differential leukocyte counts (Pentra 60C+, Horiba, Montpellier, France) and 161 
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neutrophil function. Blood collected in the 6 mL plain vacutainers was allowed to clot 162 
at room temperature for 1 h 20 min. Following centrifugation (1300 g for 10 min at 163 
4°C), serum was stored at -80°C for later metabolomic analysis. 164 
2.5. Neutrophil function 165 
Whole blood from the EDTA vacutainers was stored at room temperature (no longer 166 
than 2 h) prior to  measurement of in-vitro stimulated neutrophil oxidative burst activity 167 
response to formyl-leucyl-methionyl-phenylalanine (fMLP) using a commercially 168 
available chemiluminescence (CL) kit (ABEL, Knight Scientific Ltd, Plymouth, UK). The 169 
CL per well was measured by a microplate luminometer (FLUOstar OPTIMA, BMG 170 
Labtech, Aylesbury, UK). The contents of each microplate well that contained an fMLP 171 
stimulated sample were as follows: 20 µL of diluted whole blood (blood and Hank’s 172 
balanced salt solution; HBSS, without calcium and magnesium, at ratio of 1:100), 90 173 
µL assay buffer (HBSS with calcium and magnesium), 50 µL Pholasin and 20 μL 174 
adjuvant K (substance that enhances the luminescence of Pholasin).  175 
These mixtures were gently shaken and incubated at 37°C for 30 s in the luminometer, 176 
prior to the addition of 20 µL fMLP (10 μM) to provide an end total volume of 200 L 177 
per well, a 1:1010 final blood dilution and a fMLP concentration of 1µM respectively. 178 
The unstimulated state was calculated as the mean CL of the well prior to addition of 179 
fMLP (45 s). Following addition of fMLP, area under the curve (over 300 s), above the 180 
stable unstimulated state was used to determine stimulated CL. To calculate 181 
responses on a per cell basis, it was assumed that the stimulated CL is entirely from 182 
neutrophils (Morozov et al., 2003). Thus, fMLP-stimulated area under the CL curve 183 
was divided by the number of neutrophils present in each well to give CL in RLU (i.e. 184 
oxidative burst) per neutrophil. 185 
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2.6. Serum metabolomics 186 
To remove proteins before mass spectrometry, 20 µL of each serum sample was 187 
mixed with 30 µL of ice-cold ultrapure water and vortexed. 50 µL of ice-cold HPLC 188 
grade acetone (Fisher Scientific UK Ltd, Loughborough, UK) was then added and the 189 
mixture vortexed. Samples were left on ice for 30 min to allow protein precipitation, 190 
after which, they were centrifuged at 16 000 g for 10 min in a micro-centrifuge. After 191 
centrifugation, 50 µL of the supernatant was removed and transferred to a glass insert 192 
placed in a glass auto-sampling vial, to which 250 µL of ice-cold 70% (v/v) methanol 193 
(made up using HPLC grade methanol (Fisher Scientific UK Ltd.) and ultrapure water) 194 
was added. Seven control serum samples, from human male AB plasma (Sigma-195 
Aldrich, Dorset, UK), were run simultaneously using the same protocol to act as 196 
machine and protocol controls. 197 
 198 
Analysis was carried out using Direct Injection Electrospray Ionisation Mass-199 
Spectrometry (DI-ESI-MS) on a Micromass LCT mass-spectrometer 200 
(Micromass/Waters Ltd., UK) in negative ionization mode where metabolites are singly 201 
ionized by the loss of H+. The polar extracts were reconstituted in 0.25 mL 30% [v/v] 202 
methanol: H2O and 50 μL added to 200 μL inserts in 2 mL (Waters Ltd. UK) and 203 
introduced by direct-infusion (DI) at a flow rate of 0.05 mL min-1 in 30% [v/v] methanol: 204 
H2O running solvent. Data were acquired over the m/z range 100-1400 Th and were 205 
imported into MATLAB, binned to unit mass and then normalized to percentage total 206 
ion as stated in Johnson et al. (2007). Tentative identification of metabolites of interest 207 
was achieved through interrogation of the HMDB Serum Metabolome database 208 
(Psychogios et al., 2011).  209 
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2.7. Saliva sampling 210 
Participants reported to the laboratory for a saliva sample at baseline and 4, 8 and 12 211 
weeks following supplementation. All participants avoided strenuous exercise 24 h 212 
prior to each visit and arrived at the laboratory after an overnight fast of at least 10 h.  213 
For all saliva samples the mouth was rinsed with plain water at least 10 min before the 214 
collection period. To obtain the sample, the participant remained seated with the head 215 
tilted slightly forward and passively dribbling into a pre weighed 7 mL sterile bijou tube 216 
while keeping orofacial movement to a minimum. The final duration of collection was 217 
recorded and the tube was weighed again to allow for estimation of saliva flow rate 218 
when the density of saliva was assumed to be 1.0 gmL-1 as used in previous studies 219 
(Chicharro et al., 1998; Davison et al., 2009). With the use of a freezing point 220 
depression osmometer (Osmomat 030, Gonotec, GbBH, Berlin, Germany), saliva 221 
osmolality was determined to allow for concentration of salivary immunological 222 
parameters to be expressed relative to saliva osmolality and flow rate. Saliva samples 223 
were centrifuged for 5 min at 16000 g to allow separate storage (at -80°C) of the pellet 224 
and supernatant for later microbiome analysis and enzyme-linked immunosorbent 225 
assay (ELISA) respectively. Aliquots of saliva samples were thawed at room 226 
temperature only once prior to each ELISA. Following the thawing of saliva, samples 227 
were again centrifuged for 5 min at 16000 g to precipitate mucins and other debris and 228 
allow for the resulting clear supernatant to be analyzed. 229 
2.8. Blood contamination 230 
Aliquots of saliva were screened for blood contamination by the determination of 231 
salivary transferrin concentration using an ELISA kit (Salimetrics, State College, 232 
Pennsylvania, USA). If salivary transferrin concentration was greater than 1 mgdL-1, 233 
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the sample was considered to be contaminated with blood. If a sample at any timepoint 234 
was found to be contaminated, all salivary lysozyme (s-Lys) and lactoferrin (s-Lys) 235 
data for that participant were excluded from the study (this was not done for IgA as the 236 
ELISA was specific to sIgA, see below). 237 
2.9. Saliva sIgA  238 
The concentration of s-IgA (mgL-1) was determined in all saliva supernatants following 239 
the protocol of Leicht et al. (2011). The sandwich ELISA approach was slightly 240 
modified to include a capture antibody specific to the secretory component of human 241 
IgA (Mouse anti-human IgA secretory, Merck Millipore, Darmstadt, Germany).  242 
2.10. Saliva antimicrobial peptides 243 
All participants who were free from any contaminated samples (COL = 22, PLA = 24) 244 
were assessed for changes in s-Lys and s-Lac. Measurements were performed 245 
according to manufacturer’s instructions using commercial available ELISA kits 246 
(Assaypro LLC, St-Louis, MO). 247 
2.11. Extraction of microbial DNA 248 
Microbial DNA was extracted from 200 µL of the salivary pellet at baseline and 12 249 
weeks of 31 participants (COL = 14, PLA = 17) who all commenced the study late 250 
September/early October and completed the study late December/early January. 251 
Extraction was performed using a FastDNA SPIN Kit (MP Biomedical, Santa Ana, 252 
USA) following the manufacturer’s guidelines, except that bead beating was carried 253 
out using a FastPrep24 (MP Biomedical) machine with three cycles at speed setting 254 
6.0 for 30 s, with cooling on ice for 60 s between each cycle. Extracted DNA was 255 
quantified using Epoch (BioTek, Winooski, USA) spectrophotometry. All extractions 256 
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were confirmed to have a 260/280 nm ratio of between 1.8 and 2.0 for quality control 257 
purposes. 258 
2.12. 16S rRNA gene terminal restriction fragment length polymorphisms (T-259 
RFLP) 260 
Amplification of the 16S rRNA gene was accomplished through PCR using primers 27f 261 
(5’-AGA GTT TGA TCC TGG CTC AG-3’ with FAM labelled on 5’ end) and 1389r (5’-262 
ACG GGC GGT GTG TAC AAG-3’) as described by Huws et al. (2011). All PCR 263 
products were verified using a 1.0% agarose gel. Triplicate reactions for each sample 264 
were pooled and purified using a QIAquick PCR purification kit (Qiagen, West Sussex, 265 
UK) following the manufacturer’s guidelines. 25 ng of purified PCR product for each 266 
sample was digested for 5 h at 37°C with restriction enzymes HaeIII and MspI 267 
(Promega, Madison, USA), in separate reactions. Restriction products were separated 268 
through size using an ABI PRISM1 377 Automated DNA Sequencer (Applied 269 
Biosystems, Warrington, UK). As there was an inability to sequence the 16S rRNA 270 
genes at one of the timepoints for 2 participants, peak profiles and Shannon Diversity 271 
Indexes were determined on 29 participants only (COL= 12, PLA= 17). Peak profiles 272 
were examined using Genemapper software (Version 3.7, Applied Biosystems). 273 
Those peaks with an estimated fragment size below 50 nucleotides were removed and 274 
the remaining data were modelled using FingerPrinting II software (BioRad, Hercules, 275 
USA). Shannon Diversity Indexes were determined using Fingerprint Analysis with 276 
Missing Data software (Version 1.2) (Schluter and Harris, 2006). 277 
2.13. 16S rRNA Gene Quantitative PCR 278 
Quantitative PCR was carried out on neat extracted DNA against standards created 279 
by amplifying the 16S rRNA gene of 5 randomly selected baseline samples. This used 280 
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1 µl of each sample in a PCR reaction using 27f and 1389r primers, as detailed above, 281 
except that the 27f primer did not have FAM on the 5’ end, to amplify the gene. The 282 
resulting PCR product was purified and quantified, as previously detailed, to estimate 283 
the total number of 16S rRNA gene copies and serial dilutions made to a 10-10 level. 284 
Serial dilutions of 10-0, 10-2, 10-4, 10-6, 10-8, and 10-10 were used in subsequent qPCR 285 
reactions using a C100 thermal cycler (BioRad) and CFX96 optical detector (BioRad), 286 
with data captured using CFX Manager software (BioRad). qPCR reactions were 287 
completed in 25 µl volumes consisting of 1X SYBR Green Mastermix (Applied 288 
Biosystems), 400 nM of each of the EubF forward (5’-GTG STG CAY GGT TGT CGT 289 
CA-3’) and EubR reverse (5’-ACG TCR TCC MCA CCT TCC TC-3’) primers, as 290 
detailed by Kim et al. (2008) and 3 µl of neat DNA. The final volume was made up with 291 
PCR grade water (Roche, Hertfordshire, UK). 292 
2.14. Microbial Growth Curve Analysis 293 
To ascertain the antimicrobial properties of each supplement, 10 µl of a 50 gL-1 (w/v) 294 
solution of COL or PLA (made using autoclaved ultrapure water), were cultured with 295 
200 µL of artificial saliva medium and 10 µL of a salivary microbial culture as previously 296 
described by McBain et al. (2003). In addition, 10 µL of the COL and PLA solutions 297 
were incubated with 200 µL of artificial saliva medium, without the addition of the 298 
salivary microbial culture, to determine the level of microbial load for each solution. 299 
These cultures, alongside appropriate positive and negative growth controls, were 300 
incubated in a CellStar tissue culture 96 well plate with flat bottom and lid (Greiner Bio-301 
one, Nürtingen, Germany) in a BioTek ELx808 microplate reader (BioTek Instruments, 302 
Winooski, USA) set at 37°C for 72 h. An optical density reading was taken every 20 303 
min at a 630 nm wavelength, before which, the plate was shaken for 5 s. 304 
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 305 
Kinetic read data was exported from the Gen5 software package (BioTek Instruments) 306 
and corrected to a baseline (the first reading taken for each of the 96 wells). To allow 307 
for log transformation of the raw data, all data points, after baseline correction, were 308 
added to 10. The Log10 value for each data point was then calculated. After 3 replicate 309 
96 well plates were completed, the mean and standard deviation for each growth 310 
condition, across all 3 plates, was calculated. 311 
2.15. Statistical analyses 312 
Data shown in the text, tables and figures are presented as mean values and standard 313 
deviation unless stated otherwise. Statistical analysis of all data were performed via 314 
the statistical computer software package SPSS (v20.00; SPSS Inc., Chicago, IL, 315 
USA) unless stated otherwise. Statistical significance was accepted at P < 0.05. All 316 
immunological parameters were checked for normal distribution using the Shapiro-317 
Wilk test. Data not normally distributed (leukocyte counts, stimulated neutrophil 318 
oxidative burst, sIgA and sLys) were normalized with log transformation before further 319 
analysis.  Initially, a 2 factor mixed model ANOVA (group × time) was carried out on 320 
all immunological measures,16S rRNA (salivary bacterial load) and total peak number 321 
for HaeIII and MspI (salivary bacterial diversity) to determine if the effect of time was 322 
different between COL or PLA groups. Any significant main effects identified in the 323 
ANOVA were further analyzed by post-hoc paired t-tests with Holm-Bonferroni 324 
correction. Independent t-tests were used to determine differences between groups at 325 
baseline and 12 weeks in Shannon Diversity Indexes for TFRLP (HaeIII and MspI). 326 
Data for the proportion of reported URI days and proportion of participants who 327 
suffered URI over the 12 weeks between the COL and PLA groups were assessed by 328 
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chi-squared test. To also examine the time-course of any effect of COL, chi-squared 329 
analyses of URI at 4 week intervals were performed, in accordance with the timing of 330 
saliva collections in the current study and the methods of Crooks et al. (2006, 2010). 331 
Chi-squared analysis was also used to assess proportion of participants within COL 332 
or PLA who reported use of medication or a negative effect on training load (reduced 333 
or prevented) during URI episodes.  Comparisons between COL and PLA groups for 334 
mean number of self-reported URI episodes, mean duration of URI, mean severity of 335 
URI and mean weekly training loads were performed with an independent t-test. 336 
Metabolite data was analyzed through multivariate statistics, including principal 337 
component analysis and discriminant function analysis (DFA), using PyChem software 338 
(Jarvis et al., 2006) and following accepted Metabolomics Standard Initiative 339 
procedures (Sansone et al., 2007). Those whole mass unit bins which had a DFA 340 
loading of more than 2 standard deviations from the mean were selected for tentative 341 
identification. Determination of change from baseline for each whole mass unit bins 342 
was determined using 1-way ANOVA. 343 
3. Results 344 
3.1. Training load 345 
Analysis of IPAQ questionnaires showed no significant differences between COL (53.1 346 
± 6.0 MET-h·week-1) and PLA (48.2 ± 5.4 MET-h·week-1) groups for weekly training 347 
volume at moderate-vigorous intensity (t (51) = -0.61, p = .546).  348 
3.2. Upper respiratory illness 349 
Chi-squared analysis showed a significantly lower proportion of days with URI during 350 
the 12 weeks in the COL group (5%) compared to the PLA group (9%) (2(1) = 40.52, 351 
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p < .001). Further chi-squared analyses of URI at 4 weeks intervals showed a 352 
significantly lower proportion of days with URI in the COL group at 1-4 weeks (COL = 353 
6 %, PLA = 8%; 2 (1) = 4.56, p = .021) and 5-8 weeks (COL = 2 %, PLA = 13% ; 2 354 
(1) = 64.12, p < .001) but not 9-12 weeks (COL = 6%, PLA =7%; 2 (1) = 0.29, p = 355 
.348) (Figure 1). Independent t-test showed a significantly lower mean number of URI 356 
episodes in the COL group compared to PLA group over the 12 weeks (COL, 0.4 ± 357 
0.7; PLA, 0.8 ± 0.7; t (51) = 1.88, p = .033). The proportion of participants who reported 358 
URI during the study period (all 12 weeks combined) was not lower in the COL group 359 
(40%) than PLA group (64%) (2 (1) = 3.13, p =.067). There were, however, a 360 
significantly lower proportion of participants who reported URI in the COL group (12%) 361 
compared to PLA (36%) at 5-8 weeks (2 (1) = 0.29, p = .044) which was not evident 362 
at 1-4 weeks (COL = 16 %, PLA = 25%; 2 (1) = 0.65, p = .322) or 9-12 weeks (COL 363 
= 20 %, PLA =18%; 2 (1) = 0.04, p = .559) (Figure1). When URI episodes were 364 
reported by participants, the severity (COL, 35.3 ± 26.9; PLA, 42.0 ± 27.4; t (32) = 365 
0.68, p = .250) and duration of symptoms (COL, 7.9 ± 4.4 days; PLA, 9.9 ± 5.6; t (32) 366 
= 1.02, p = .159) were similar between groups. During episodes of URI, there were no 367 
differences between groups for the proportion of participants who used medication 368 
(COL = 50%, PLA =78%; 2 (1) = 2.27, p =.139) or had training negatively affected 369 
(i.e. reduced or prevented) (COL = 60%, PLA =54%; 2 (1) = 1.15, p =.249). All of the 370 
above patterns/effects were similar in the subset of participants used for microbiome 371 
analysis (see section 2.11). 372 
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3.3. Cell counts and neutrophil function 373 
Results for total and differential leukocyte counts, and stimulated neutrophil oxidative 374 
burst, at baseline and 12 weeks following supplementation in COL and PLA groups 375 
are shown in Table 1.  376 
3.4. Salivary sIgA and antimicrobial peptides  377 
The analyses of salivary antimicrobial peptides across the 12 week period are shown 378 
in Table 2 and 3. One participant was removed from sIgA analysis due to a lack of 379 
clear supernatant upon centrifugation of saliva samples. Final comparison for sIgA 380 
was conducted on 52 participants (COL = 25, PLA = 27). This participant had been 381 
excluded from sLac and sLys for contamination purposes as previously mentioned 382 
(see above). There were no significant differences between groups in salivary 383 
measures during the 12 weeks (P > .05) (Table 2 and 3). 384 
3.5. Salivary bacterial load and diversity 385 
The ANOVA to analyze log of estimated copy number of 16S rRNA gene revealed a 386 
significant time (F (1,29)= 15.38, p < .001) and interaction effect (F (1,29)= 4.90, p = 387 
0.035)  but no group effect (F (1,29)= 0.28, p = .602) (Figure 2). Post-hoc analysis of 388 
interaction revealed a significant increase in bacterial load over the 12 weeks in the 389 
PLA group (t (16)= -6.64, p < .001) that was not present in COL group (t (16)= -0.90, 390 
p = 0.386) (Figure 2). ANOVA on total TRFLP peak number obtained from the 391 
restriction enzyme MspI revealed a main time effect (F (1,27)= 21.80, p < .001), with 392 
decreased bacterial diversity at 12 weeks, but no interaction (F (1,27) = 0.43, p = .515) 393 
or group effect (F (1,27) = 0.01, p = .917). However, analysis of total TRFLP peak 394 
number using HaeIII revealed no time (F (1,27)= 2.54, p = .123), interaction (F (1,27) 395 
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= 0.13, p = .912) or group effects (F (1,27) = 0.29, p = .866). Analysis of Shannon 396 
Diversity Indexes for TFRLP using MspI showed no differences between groups at 397 
baseline (t (29)= 0.27, p = .789) or at 12 weeks (t (28)= 0.33, p = .746) . There were 398 
also no differences at baseline (t (28)= 0.41, p = .683) or 12 weeks (t (28)= 0.23, p = 399 
.823) in Shannon Diversity Indexes for TFRLP using HaeIII. Microbial growth analysis, 400 
shown in Supplementary Figure 1, showed no indication of a direct antimicrobial effect 401 
of either the COL or PLA supplement. 402 
3.6. Metabolomics    403 
Sugisawa et al. (2003) have suggested that low molecular weight (< 10 kDa) 404 
substances may be responsible for the immunological effects of COL. We therefore 405 
used a metabolomics approach to determine whether COL increased the 406 
concentration of compounds at the lower end of this range (<1.4 kDa) with the 407 
expectation that any such effects would be due to bioactive metabolites. Thus, 408 
metabolite profiles of serum derived using DI-ESI-MS were analysed using 409 
multivariate approaches. DFA of serum profiles at baseline and at 12 weeks (Figure 410 
3), showed no separation, at either time point, between the COL and PLA groups. 411 
However, there was clear separation between the two time points. Interrogation of the 412 
loading vectors selected by the algorithm to derive DF1 suggested that 13 m/z were 413 
calculated to be the major sources of variation. Interrogation of the HMDB Serum 414 
Metabolome database allowed the tentative identification of these 13 metabolites 415 
(Table 4). Within the tentative identifications, there are several possibilities for each 416 
m/z but no particular biochemical pathways or immunological metabolite markers 417 
appeared to have been targeted. 418 
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4. Discussion 419 
This study aimed to determine the effects of COL on innate and mucosal markers of 420 
immunity and the subsequent incidence of URI in regularly exercising males. 421 
Compared to the PLA group, there was a significantly lower number of URI episodes 422 
and subsequently less proportion of URI days in the COL group over the 12 weeks. 423 
This supports previous evidence in studies of both active and immune-deficient 424 
populations (Brinkworth and Buckley, 2003; Crooks et al., 2010; Patel and Rana, 425 
2006). Beneficial effects of COL were most evident during periods of greater 426 
prevalence of URI within the study population by reducing the proportion of 427 
participants who report URI (hence a greater scope for intervention). As not all 428 
participants commenced the study at the same time of year, it is important to recognize 429 
that these findings reflect the effects of COL within the timeframe and the incidence of 430 
illness in participants of the current study rather than proposing a specific seasonal 431 
window where COL affects URI. There was, however, no effect of COL on severity 432 
and duration of URI episodes, which supports some previous studies (Brinkworth and 433 
Buckley, 2003; Crooks et al., 2006, 2010) but not the beneficial effects reported by 434 
Patiroglu and Kondolot (2011). 435 
In contrast to the effect of COL on URI, there was no significant effect of COL on 436 
salivary sIgA and AMPs or fMLP-stimulated blood neutrophil oxidative burst. The lack 437 
of effect on immune parameters despite differences in URI is in accordance with 438 
previous evidence (Crooks et al., 2006; Shing et al., 2007). Although previous studies 439 
have found beneficial effects in mucosal protection (sIgA/AMPs) following COL 440 
supplementation, either a blunting of the exercise-induced immune dysfunction 441 
(Davison and Diment, 2010) or increased resting salivary sIgA (Crooks et al., 2006), 442 
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they did not measure URI (Davison and Diment, 2010) or failed to see  simultaneous 443 
effects of COL on URI (Crooks et al., 2006). This has led to proposals that the effect 444 
of COL occurs through a combination of mechanisms (Shing et al., 2007). In the 445 
current study we proposed the use of a novel in-vivo marker (salivary microbiome) that 446 
may have greater sensitivity to changes in innate mucosal defense following an 447 
intervention.  This study shows for the first time that during regular training in the winter 448 
months, COL limits the increase in salivary bacterial load that was observed in the 449 
PLA group. However it is currently unclear whether the significant increase in bacterial 450 
load in the PLA group played a role in the greater episodes of URI observed in this 451 
group or whether the increased bacterial load occurred as result of a greater number 452 
of illnesses, or compromised immunity (due to training and/or seasonal effects) . 453 
Future studies should investigate salivary bacterial load at the taxonomic level with 454 
next generation sequencing methods to determine whether changes reflect 455 
predisposed interactions with viruses which are the common cause of URI (Bosch et 456 
al., 2013).  457 
Evidence from respiratory health research has suggested that bacterial colonization 458 
of tissues contiguous to the oral cavity (e.g. airway) can trigger an increase in the 459 
frequency of disease exacerbations (Wedzicha and Donaldson, 2003). Furthermore, 460 
the interaction between viruses and bacteria which colonize the upper respiratory tract 461 
has been highlighted to affect the risk of illness (Bosch et al., 2013). Of relevance to 462 
this study are suggestions that the balance of microbes involved in colonization can 463 
be perturbed when host immunity is compromised (Murphy et al., 2009). It is apparent 464 
that the magnitude of change in immunity immediately following each bout of 465 
strenuous exercise may have more clinical significance than training-induced 466 
alterations in resting immunity (Abhassi et al., 2013; Nieman et al., 1994; Pedersen 467 
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and Bruunsgaard, 1995). It is reasonable to suggest that over the course of the 12 468 
weeks the COL group suffered fewer incidences of transient immune perturbations, 469 
and/or smaller or shorter disturbance, (in response to training and/or seasonal 470 
variation) which may have limited conditions for changes in the salivary microbiome to 471 
occur. COL has been shown to prevent exercise-induced decreases in salivary AMPs 472 
and improve recovery of the capacity of neutrophils (a source of AMPs) following 473 
strenuous exercise (Davison and Diment, 2010). Deficiencies or decreases in AMPs 474 
expressed in mucosal secretions have been shown to be related to greater bacterial 475 
invasion and/or cases of infection (Bals et al., 1998, 1999; Daele and Zicot, 2000; 476 
Smith et al., 1996; Goldman et al., 1997). It is worthy to note, however, that the present 477 
study has only investigated a narrow range of AMPs that are present in mucosal 478 
secretions. Therefore, the effects of COL on the resting concentrations of other AMPs 479 
such as cathelicidins, which have broad anti-bactericidal effects (Bals, 2000), remain 480 
unclear and cannot be excluded. In addition, there were no apparent effects of COL 481 
on in-vitro microbial culture in this study which supports that the aforementioned 482 
effects on bacterial load are not due to components of COL having direct anti-microbial 483 
effects in the oral cavity during consumption. 484 
Of particular note was the lack of simultaneous increase in bacterial diversity within 485 
the PLA group during the study. This suggests that it was not the acquisition of new 486 
bacteria that caused the significant increase in bacterial load in the PLA group but 487 
rather amplification of bacteria resident at baseline. The oral cavity is exposed to a 488 
constant array of exogenous and endogenous factors, thus measurement via saliva 489 
has been recognized to provide a ‘fingerprint’ of the whole oral microbiota (Dewhirst 490 
et al., 2010; Fabian et al., 2008; Li et al., 2005; Boutaga et al., 2007). We propose that, 491 
rather than causing URI per se, an increase in bacterial load is indicative of 492 
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compromised innate immune status, and as such is a relevant marker of in-vivo 493 
(innate) immune status. Furthermore, if COL supplementation does limit increases in 494 
salivary bacterial load, it will be important to determine whether this is a general 495 
reduction in bacteria, or whether it is biased towards certain bacterial taxonomies.  496 
A further aim of this study was to determine any metabolomic changes as a result of 497 
COL supplementation. Metabolomics provides an unbiased biochemical “snap shot” 498 
of samples which due to the use of high resolution MS-based (as here) or nuclear 499 
magnetic resonance (NMR)-based approaches simultaneously and accurately 500 
measure hundreds of metabolites. Exercise immunologists view that high throughput 501 
laboratory methods such as metabolomics will provide greater understanding of the 502 
mechanisms behind modulations of the immune system with exercise and/or nutrition 503 
(Walsh et al., 2011). Crucially, in this study, we did not observe any changes in serum 504 
metabolome linked to COL supplementation, indicating that either no major changes 505 
were occurring or that these were occurring below the detection limits of the Mass 506 
Spectrometer (<10-12 mol, Sumner et al., 2003). There was, however, a clear 507 
separation of metabolome profiles obtained at baseline and at the 12 week timepoint 508 
of the study. The timepoint effect could reflect a combination of a seasonal effect and 509 
accumulation of training stress. As seasonal and/or exercise effects alone on the 510 
immune system were not a primary aim of the study, future studies should investigate 511 
whether changes in metabolome are involved in the greater incidence of URI seen in 512 
the winter months. Confirmatory identifications of the 13 m/z which appear to be 513 
responsible for the majority of the temporal separation were not accomplished as 514 
changes in the serum metabolome were not as a result of COL supplementation and 515 
thus fell outside of the scope of this project. 516 
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Previous in-vitro culture studies suggested that low molecular weight (≤ 10 kDa) 517 
components of COL (e.g. proteose peptones) rather than larger growth factors or 518 
cytokines may be responsible for the effects on human immune function (e.g. 519 
leukocyte capacity) (Sugiswa et al., 2003). Given that our metabolomics approach 520 
provides data on (<1.4 kDa) metabolites involved in biological pathways (Holmes et 521 
al., 2008), it may have been expected to identify traces of such bioactive metabolites 522 
in the circulation following 12 weeks of supplementation. Future studies could 523 
additionally examine components between 1.4-10 kDA to identify whether the above 524 
mentioned components of COL investigated within in-vitro culture become 525 
bioavailable to affect human immune function following periods of supplementation. 526 
Such studies will help identify the bioactive components and eradicate discrepancies 527 
found between studies of COL that are due to the source/quality of the supplement 528 
(Davison, 2013).  It is plausible, however, to suggest that in the present study the 529 
proposed priming effects may have been localised to immune parameters in the 530 
mucosae rather than having systemic effects. Another proposed mechanism behind 531 
the effects on URI is the ability of COL to truncate the increase in gut permeability 532 
following strenuous exercise (Marchbank et al., 2011). This effect on intestinal integrity 533 
may prevent additional stress on the immune system via the translocation of luminal 534 
bacteria into systemic circulation. This hypothesis, however, requires further study in 535 
relation to episodes of URI. 536 
Although previous studies have shown inconsistencies in isolated immune markers at 537 
rest, the present study suggests that the effects of COL are apparent when an 538 
integrated and interactive holistic immune marker is taken (e.g. salivary bacterial load). 539 
It should be noted that participants in this study were not limited in their use, either 540 
before or during the study, of mouthwash. This could be considered a potential 541 
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limitation of the study and an important consideration for future studies using the 542 
salivary bacterial load as an in-vivo marker. Given the presence of null findings in the 543 
present study compared to previous studies of investigated immune parameters (e.g. 544 
sIgA), it is important to acknowledge methodological limitations not yet considered. 545 
The present study involved participants who were involved in a range of sports 546 
training. Although these were all endurance based activities, previous studies have 547 
reported that effects of COL on sIgA may not be universal in all groups of regular 548 
exercisers (Crooks et al., 2010). In addition, it is unclear whether the use of participants 549 
who had a higher mean weekly training load and hence potentially a greater number 550 
of immunodepressive bouts would have produced different findings for these 551 
measures. Indeed, when highly trained cyclists completed 5 consecutive days of high-552 
intensity training, COL supplementation was found to prevent the decreases in 553 
cytotoxic/suppressor T cells observed at the end and in the recovery period from the 554 
training in the PLA group (Shing et al., 2007).  555 
In summary, we have shown for the first time that COL supplementation can limit 556 
microbial changes in the oral cavity during the winter months. This may be due to COL 557 
acting as a nutritional countermeasure to seasonal effects on salivary microbiome or 558 
immune perturbations following acute exercise. The clinical implications of this may 559 
be a reduction in the number of URI episodes. Future research should include 560 
responses to acute training during the monitoring period to determine the effects on 561 
the salivary microbiome and whether COL influences these (and other, e.g. AMPs) 562 
responses. 563 
 564 
Acknowledgements 565 
25 
 
We acknowledge the assistance of Kirsten Skøt and Sharon Huws with the T-RFLP 566 
sequencing and T-RFLP technique/creation of artificial saliva media respectively. 567 
Arwel W. Jones’ PhD was supported by a Knowledge Economy Skills Scholarship 568 
which was a collaborative project with an external partner, The Golden Dairy Ltd 569 
(supplier for Neovite UK). This project was part-funded by the European Social Fund 570 
through the European Union's Convergence Programme (West Wales and the 571 
Valleys) and administered by the Welsh Government. 572 
  573 
26 
 
References 574 
Abbasi, A., Fehrenbach, E., Hauth, M., Walter, M., Hudemann, J., Wank, V., Niess, 575 
A.M., Northoff, H., 2013. Exerc Immunol Rev 19, 8-28.  576 
Appukutty, M., Radhakrishnan, A., Ramasamy, K., Majeed, A.B.A., Chinna, K., Noor, 577 
I.M., Safii, N. K., Koon, P. B., 2010. Br. J. Sports Med. 44, 145.    578 
Bals, R., 2000. Epithelial antimicrobial peptides in host defense against infection. 579 
Respir. Res. 1, 141-150. 580 
Bals, R., Wang, X., Zasloff, M., Wilson, J.M., 1998. The peptide antibiotic LL-581 
37/hCAP-18 is expressed in epithelia of the human lung where it has broad 582 
antimicrobial activity at the airway surface. Proc. Natl. Acad. Sci. U. S. A 95, 9541-583 
9546. 584 
Bals, R., Weiner, D.J., Moscioni, A.D., Meegalla, R.L., Wilson, J.M., 1999. 585 
Augmentation of innate host defense by expression of a cathelicidin antimicrobial 586 
peptide. Infect. Immun. 67, 6084-6089. 587 
Biswas, P., Vecchi, A., Mantegani, P., Mantelli, B., Fortis, C., Lazzarin, A., 2007. 588 
Immunomodulatory effects of bovine colostrum in human peripheral blood 589 
mononuclear cells. New. Microbiol. 30, 447-454. 590 
Blaser, M.J., Falkow, S., 2009. What are the consequences of the disappearing 591 
human microbiota? Nat. Rev. Microbiol. 7, 887-894. 592 
Bosch, A.A., Biesbroek, G., Trzcinski, K., Sanders, E.A., Bogaert, D., 2013. Viral and 593 
bacterial interactions in the upper respiratory tract. PLoS Pathog . 9, e1003057. 594 
Boudry, C., Buldgen, A., Portetelle, D., Gianello, P., Thewis, A., Leterme, P., 595 
Dehoux, J.P., 2007. Effect of bovine colostrum supplementation on cytokine mRNA 596 
expression in weaned piglets. Livest. Sci. 108, 295-298. 597 
27 
 
Boutaga, K., Savelkoul, P.H., Winkel, E.G., van Winkelhoff, A.J., 2007. Comparison 598 
of subgingival bacterial sampling with oral lavage for detection and quantification of 599 
periodontal pathogens by real-time polymerase chain reaction. J. Periodontol. 78, 600 
79-86. 601 
Brinkworth, G.D., Buckley, J.D., 2003. Concentrated bovine colostrum protein 602 
supplementation reduces the incidence of self-reported symptoms of upper 603 
respiratory tract infection in adult males. Eur. J. Nutr. 42, 228-232. 604 
Chicharro, J.L., Lucia, A., Perez, M., Vaquero, A.F., Urena, R., 1998. Saliva 605 
composition and exercise. Sports Med. 26, 17-27. 606 
Craig, C.L., Marshall, A.L., Sjostrom, M., Bauman, A.E., Booth, M.L., Ainsworth, 607 
B.E., Pratt, M., Ekelund, U., Yngve, A., Sallis, J.F., Oja, P., 2003. International 608 
physical activity questionnaire: 12-country reliability and validity. Med. Sci. Sports 609 
Exerc. 35, 1381-1395. 610 
Crooks, C., Cross, M.L., Wall, C., Ali, A., 2010. Effect of bovine colostrum 611 
supplementation on respiratory tract mucosal defenses in swimmers. Int. J. Sport 612 
Nutr. Exerc. Metab. 20, 224-235. 613 
Crooks, C.V., Wall, C.R., Cross, M.L., Rutherfurd-Markwick, K.J., 2006. The effect of 614 
bovine colostrum supplementation on salivary IgA in distance runners. Int. J. Sport 615 
Nutr. Exerc. Metab. 16, 47-64. 616 
Daele, J., Zicot, A.F., 2000. Humoral immunodeficiency in recurrent upper 617 
respiratory tract infections. Some basic, clinical and therapeutic features. Acta 618 
Otorhinolaryngol. Belg. 54, 373-390. 619 
Davison, G., 2013. Bovine colostrum and immune function after exercise. In: 620 
Lamprecht, M. (Ed.), Acute topics in sports nutrition. Karger, Basel, pp. 62-69. 621 
28 
 
Davison, G., Allgrove, J., Gleeson, M., 2009. Salivary antimicrobial peptides (LL-37 622 
and alpha-defensins HNP1-3), antimicrobial and IgA responses to prolonged 623 
exercise. Eur. J. Appl. Physiol. 106, 277-284. 624 
Davison, G., Diment, B.C., 2010. Bovine colostrum supplementation attenuates the 625 
decrease of salivary lysozyme and enhances the recovery of neutrophil function after 626 
prolonged exercise. Br. J. Nutr. 103, 1425-1432. 627 
Dewhirst, F.E., Chen, T., Izard, J., Paster, B.J., Tanner, A.C., Yu, W.H., 628 
Lakshmanan, A., Wade, W.G., 2010. The human oral microbiome. J. Bacteriol. 192, 629 
5002-5017. 630 
Fabian, T.K., Fejerdy, P., Csermely, P., 2008. Salivary Genomics, Transcriptomics 631 
and Proteomics: The Emerging Concept of the Oral Ecosystem and their Use in the 632 
Early Diagnosis of Cancer and other Diseases. Curr. Genomics 9, 11-21. 633 
Fricker, P.A., Pyne, D.B., Saunders, P.U., Cox, A.J., Gleeson, M., Telford, R.D., 634 
2005. Influence of training loads on patterns of illness in elite distance runners. Clin. 635 
J. Sport Med. 15, 246-252. 636 
Gleeson, M., 2007. Immune function in sport and exercise. J. Appl. Physiol. 103, 637 
693-699. 638 
Gleeson, M., Bishop, N.C., Oliveira, M., McCauley, T., Tauler, P., Lawrence, C., 639 
2012. Effects of a Lactobacillus salivarius probiotic intervention on infection, cold 640 
symptom duration and severity, and mucosal immunity in endurance athletes. Int. J. 641 
Sport Nutr. Exerc. Metab. 22, 235-242. 642 
Gleeson, M., Bishop, N.C., Oliveira, M., Tauler, P., 2011. Daily probiotic's 643 
(Lactobacillus casei Shirota) reduction of infection incidence in athletes. Int. J. Sport 644 
Nutr. Exerc. Metab. 21, 55-64. 645 
29 
 
Goldman, M.J., Anderson, G.M., Stolzenberg, E.D., Kari, U.P., Zasloff, M., Wilson, 646 
J.M., 1997. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is 647 
inactivated in cystic fibrosis. Cell 88, 553-560. 648 
Holmes, E., Wilson, I.D., Nicholson, J.K., 2008. Metabolic phenotyping in health and 649 
disease. Cell 134, 714-717. 650 
Huws, S.A., Kim, E.J., Lee, M.R., Scott, M.B., Tweed, J.K., Pinloche, E., Wallace, 651 
R.J., Scollan, N.D., 2011. As yet uncultured bacteria phylogenetically classified as 652 
Prevotella, Lachnospiraceae incertae sedis and unclassified Bacteroidales, 653 
Clostridiales and Ruminococcaceae may play a predominant role in ruminal 654 
biohydrogenation. Environ. Microbiol. 13, 1500-1512. 655 
Jarvis, R.M., Broadhurst, D., Johnson, H., O'Boyle, N.M., Goodacre, R., 2006. 656 
PYCHEM: a multivariate analysis package for python. Bioinformatics 22, 2565-2566. 657 
Johnson, H.E., Lloyd, A.J., Mur, L.A.J., Smith, A.R., Causton, D.R., 2007. The 658 
application of MANOVA to analyse Arabidopsis thaliana metabolomic data from 659 
factorially designed experiments. Metabolomics 3, 517-530. 660 
Kim, E.J., Huws, S.A., Lee, M.R.F., Wood, J.D., Muetzel, S.M., Wallace, R.J., 661 
Scollan, N.D., 2008. Fish oil increases the duodenal flow of long chain 662 
polyunsaturated fatty acids and trans-11 18:1 and decreases 18:0 in steers via 663 
changes in the rumen bacterial community. J Nutr. 138, 889-896. 664 
Leicht, C.A., Bishop, N.C., Goosey-Tolfrey, V.L., 2011. Mucosal Immune Responses 665 
to Treadmill Exercise in Elite Wheelchair Athletes. Med. Sci. Sport Exer. 43, 1414-666 
1421. 667 
Li, Y., Ku, C.Y., Xu, J., Saxena, D., Caufield, P.W., 2005. Survey of oral microbial 668 
diversity using PCR-based denaturing gradient gel electrophoresis. J. Dent. Res. 84, 669 
559-564. 670 
30 
 
Marchbank, T., Davison, G., Oakes, J.R., Ghatei, M.A., Patterson, M., Moyer, M.P., 671 
Playford, R.J., 2011. The nutriceutical bovine colostrum truncates the increase in gut 672 
permeability caused by heavy exercise in athletes. Am. J. Physiol. Gastrointest. 673 
Liver. Physiol. 300, 477-484. 674 
McBain, A.J., Bartolo, R.G., Catrenich, C.E., Charbonneau, D., Ledder, R.G., Gilbert, 675 
P., 2003. Effects of a chlorhexidine gluconate-containing mouthwash on the vitality 676 
and antimicrobial susceptibility of in vitro oral bacterial ecosystems. Appl. Environ. 677 
Microbiol. 69, 4770-4776. 678 
Mero, A., Kahkonen, J., Nykanen, T., Parviainen, T., Jokinen, I., Takala, T., Nikula, 679 
T., Rasi, S., Leppaluoto, J., 2002. IGF-I, IgA, and IgG responses to bovine colostrum 680 
supplementation during training. J. Appl. Physiol. 93, 732-739. 681 
Morozov, V.I., Pryatkin, S.A., Kalinski, M.I., Rogozkin, V.A., 2003. Effect of exercise 682 
to exhaustion on myeloperoxidase and lysozyme release from blood neutrophils. Eur 683 
J. Appl. Physiol. 89, 257-262. 684 
Murphy, T.F., Bakaletz, L.O., Smeesters, P.R., 2009. Microbial interactions in the 685 
respiratory tract. Pediatr. Infect. Dis. J 28, S121-126. 686 
Nieman, D.C., 2000. Special feature for the Olympics: effects of exercise on the 687 
immune system: exercise effects on systemic immunity. Immunol. Cell Biol. 78, 496-688 
501. 689 
Nieman, D.C., 2007. Marathon training and immune function. Sports Med. 37, 412-690 
415. 691 
Nieman, D.C., Miller, A.R., Henson, D.A., Warren, B.J., Gusewitch, G., Johnson, 692 
R.L., Davis, J.M., Butterworth, D.E., Herring, J.L., Nehlsencannarella, S.L., 1994. 693 
Effect of High-Intensity Versus Moderate-Intensity Exercise on Lymphocyte 694 
Subpopulations and Proliferative Response. Int. J. Sports Med. 15, 199-206. 695 
31 
 
Patel, K., Rana, R., 2006. Pedimune in recurrent respiratory infection and diarrhoea--696 
the Indian experience--the pride study. Indian J. Pediatr. 73, 585-591. 697 
Patiroglu, T., Kondolot, M., 2013. The effect of bovine colostrum on viral upper 698 
respiratory tract infections in children with immunoglobulin A deficiency. Clin. Respir. 699 
J. 7, 21-26. 700 
Pedersen, B.K., Bruunsgaard, H., 1995. How Physical Exercise Influences the 701 
Establishment of Infections. Sports Med. 19, 393-400. 702 
Psychogios, N., Hau, D.D., Peng, J., Guo, A.C., Mandal, R., Bouatra, S., Sinelnikov, 703 
I., Krishnamurthy, R., Eisner, R., Gautam, B., Young, N., Xia, J., Knox, C., Dong, E., 704 
Huang, P., Hollander, Z., Pedersen, T.L., Smith, S.R., Bamforth, F., Greiner, R., 705 
McManus, B., Newman, J.W., Goodfriend, T., Wishart, D.S., 2011. The human 706 
serum metabolome. PLoS One 16, e16957.  707 
Sansone, S.A., Fan, T., Goodacre, R., Griffin, J.L., Hardy, N.W., Kaddurah-Daouk, 708 
R., Kristal, B.S., Lindon, J., Mendes, P., Morrison, N., Nikolau, B., Robertson, D., 709 
Sumner, L.W., Taylor, C., van der Werf, M., van Ommen, B., Fiehn, O., 2007. The 710 
metabolomics standards initiative. Nat. Biotechnol. 25, 846-848. 711 
Schluter, P.M., Harris, S.A., 2006. Analysis of multilocus fingerprinting data sets 712 
containing missing data. Mol. Ecol. Notes 6, 569-572. 713 
Sethi, S.K., Bianco, A., Allen, J.T., Knight, R.A., Spiteri, M.A., 1997. Interferon-714 
gamma (IFN-gamma) down-regulates the rhinovirus-induced expression of 715 
intercellular adhesion molecule-1 (ICAM-1) on human airway epithelial cells. Clin. 716 
Exp. Immunol. 110, 362-369. 717 
Shing, C.M., Peake, J.M., Suzuki, K., Jenkins, D.G., Coombes, J.S., 2009. Bovine 718 
colostrum modulates cytokine production in human peripheral blood mononuclear 719 
32 
 
cells stimulated with lipopolysaccharide and phytohemagglutinin. J. Interferon 720 
Cytokine Res. 29, 37-44. 721 
Shing, C.M., Peake, J., Suzuki, K., Okutsu, M., Pereira, R., Stevenson, L., Jenkins, 722 
D.G., Coombes, J.S., 2007. Effects of bovine colostrum supplementation on immune 723 
variables in highly trained cyclists. J. Appl. Physiol. 102, 1113-1122. 724 
Smith, J.J., Travis, S.M., Greenberg, E.P., Welsh, M.J., 1996. Cystic fibrosis airway 725 
epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85, 229-726 
236. 727 
Spence, L., Brown, W.J., Pyne, D.B., Nissen, M.D., Sloots, T.P., McCormack, J.G., 728 
Locke, A.S., Fricker, P.A., 2007. Incidence, etiology, and symptomatology of upper 729 
respiratory illness in elite athletes. Med. Sci. Sports Exerc. 39, 577-586. 730 
Sugisawa, H., Itou, T., Ichimura, Y., Sakai, T., 2002. Bovine milk enhances the 731 
oxidative burst activity of polymorphonuclear leukocytes in low concentrations. J. 732 
Vet. Med. Sci. 64, 1113-1116. 733 
Sugisawa, H., Itou, T., Saito, M., Moritomo, T., Miura, Y., Sakai, T., 2003. A low-734 
molecular-weight fraction of bovine colostrum and milk enhances the oxidative burst 735 
activity of polymorphonuclear leukocytes. Vet. Res. Commun. 27, 453-461. 736 
Sugisawa, H., Itou, T., Sakai, T., 2001. Promoting effect of colostrum on the 737 
phagocytic activity of bovine polymorphonuclear leukocytes in vitro. Biol. Neonate 738 
79, 140-144. 739 
Sumner, L.W., Mendes, P., Dixon, R.A., 2003. Plant metabolomics: large-scale 740 
phytochemistry in the functional genomics era. Phytochemistry 62, 817-836. 741 
Walsh, N.P., Gleeson, M., Shephard, R.J., Woods, J.A., Bishop, N.C., Fleshner, M., 742 
Green, C., Pedersen, B.K., Hoffman-Goetz, L., Rogers, C.J., Northoff, H., Abbasi, A., 743 
33 
 
Simon, P., 2011. Position statement. Part one: Immune function and exercise. Exerc. 744 
Immunol. Rev. 17, 6-63. 745 
Wedzicha, J.A., Donaldson, G.C., 2003. Exacerbations of chronic obstructive 746 
pulmonary disease. Respir Care 48, 1204-1213; discussion 1213-1205. 747 
West, N.P., Pyne, D.B., Renshaw, G., Cripps, A.W., 2006. Antimicrobial peptides 748 
and proteins, exercise and innate mucosal immunity. FEMS Immunol. Med. 749 
Microbiol. 48, 293-304. 750 
 751 
 752 
  753 
34 
 
Fig. 1. URI during 4 week intervals in bovine colostrum (COL)/placebo(PLA) groups. 754 
Columns reflect proportion of participants in each group who report URI. Line and 755 
symbol represent proportion of URI days in each group during 4 week intervals.  756 
**Significantly lower proportion of URI days in COL group at 1-4 weeks and 5-8 weeks 757 
(p<.05). * Significantly lower proportion of participants in the COL group who report 758 
URI at 5-8 weeks (p<.05). 759 
 760 
Fig. 2. Salivary bacterial load in bovine colostrum (COL)/ placebo (PLA) groups. 761 
Standard deviation as error bars. *Significant increase in salivary bacterial load from 762 
baseline to 12 weeks in PLA group (p<.001). 763 
 764 
Fig. 3. Discriminant Function analysis (DFA) plot of metabolomic profiles before and 765 
at end of 12 weeks of bovine colostrum (COL)/placebo (PLA) supplementation.  766 
● - PLA group at baseline; ■ - COL group at baseline; ● - PLA group at 12 weeks; ■ - 767 
COL group at 12 weeks. A satisfactory separation was obtained between time points 768 
but not groups. Rings on figure display 95% confidence intervals for DFA separation. 769 
 770 
Table 1. Blood leukocytes and neutrophil function in bovine colostrum (COL)/placebo 771 
(PLA) groups. Statistically significant difference between baseline and 12 week 772 
measures (main effect of time) indicated by * p <.05. Values are mean ± SD. 773 
 774 
Table 2. sIgA before, during and at the end of 12 weeks of bovine colostrum 775 
(COL)/placebo (PLA) supplementation. Values are mean ± SD. 776 
 777 
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Table 3. sLac and sLys before, during and at end of 12 weeks of bovine colostrum 778 
(COL)/placebo (PLA) supplementation. Values are mean ± SD. Main effect of time 779 
indicated by * p <.05.  Post hoc analysis could not reveal any significant differences 780 
between timepoints for sLac concentration. There was a significant increase in sLac 781 
secretion rate (at 8 and 12 weeks) and sLys secretion rate (at 8 weeks) from baseline 782 
(p <.05). Values are mean ± SD. 783 
 784 
Table 4. Tentative identifications of metabolites which may be responsible for the 785 
separation between the 2 timepoints visible in DF1 of Figure 3.  For some of the whole 786 
number molecular weight bins there are multiple tentative IDs which may or may not 787 
contribute to the DF1 loading. Change from the baseline and subsequent ANOVA P 788 
values are detailed alongside the tentative IDs. 789 
  790 
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Immune measure 
 
 
 
Baseline 
 
 
 
12 weeks 
 
 
 
       F (df) P   time 
       F (df) P   trial 
F (df) P   interaction 
Total leukocytes (cells ×109L-1)  1.74 (1,51) .193 
COL 4.74 ± 1.02 4.90 ± 1.01 0.78 (1,51) .382 
PLA 5.20 ± 1.68 5.27 ± 1.63 0.17 (1,51) .687 
Neutrophils  (cells ×109L-1)  0.86 (1,51) .359 
COL 2.31 ± 0.61 2.31 ± 0.59 0.51 (1,51) .268 
PLA 2.58 ± 1.18 2.74 ± 1.28 1.26 (1,51) .480 
Monocytes (cells ×109L-1)   0.33 (1,51) .567 
COL 0..46 ± 0.11 0.46 ± 0.12 0.09 (1,51) .766 
PLA 0.46 ± 0.13 0.47 ± 0.20 0.63 (1,51) .431 
Total lymphocytes  (cells ×109L-1)  0.26 (1,51) .619 
COL 1.77 ± 0.50 1.91 ± 0.67 <0.01 (1,51) .970 
PLA 1.90 ± 0.61 1.79 ± 0.47 3.21 (1,51) .079 
Atypical lymphocytes (cells ×109L-1)    2.92 (1,51) .093 
COL 0.04 ± 0.01 0.04 ± 0.02 0.56 (1,51) .458 
PLA 0.05 ± 0.02 0.05 ± 0.02 2.44 (1,51) .124 
Large immature cells (cells ×109L-1)   0.05 (1,51) .832 
COL 0.03 ± 0.01 0.03 ± 0.02 1.08 (1,51) .305 
PLA 0.05 ± 0.04 0.04 ± 0.03 0.27 (1,51) .605 
40 
 
Table 1. Blood leukocytes and neutrophil function in bovine colostrum (COL)/placebo 804 
(PLA) groups. Statistically significant difference between baseline and 12 week 805 
measures (main effect of time) indicated by * p <.05. Values are mean ± SD. 806 
fMLP-stimulated CL per neutrophil  (RLU per  s-1 per cell-1)               5.31 (1,51) .025* 
COL 43.65 ± 27.44 53.99 ± 26.51 0.68 (1,51) .413 
PLA 42.79 ± 25.58 44.52 ± 24.91 0.84 (1,51) .365 
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Table 2. sIgA before, during and at the end of 12 weeks of bovine colostrum (COL)/placebo (PLA) supplementation. Values are mean 807 
± SD. 808 
 809 
 810 
 811 
 812 
 813 
 814 
 815 
 816 
 817 
 818 
 819 
 820 
 821 
 822 
Immune measure Baseline 4 weeks 8 weeks 12 weeks F (df) P time 
F (df) P trial 
F (df) P  interaction 
sIgA concentration (mgL-1)    0.71 (1,50) .404 
COL 267.0 ± 126.5 252.9 ± 119.7 256.0 ± 142.8 272.2 ± 152.5 1.09 (1,50) .301 
PLA 259.9 ± 202.9 217.1 ± 124.4 230.4 ± 132.3 215.0 ± 98.5 0.37 (1,50) .546 
sIgA secretion rate (gmin-1)    2.66 (1,50) .065 
COL 116.5 ± 89.3 125.6 ± 105.6 129.5 ± 89.6 143.9 ± 96.8 1.65 (1,50) .733 
PLA   121.1 ± 125.9 104.7 ± 51.5 114.3 ± 63.0 108.1 ± 57.3 0.12 (1,50) .180 
sIgA:osmolality (mgmOsmol-1)    0.97 (1,50) .409 
COL 3.8 ± 1.5 3.6 ± 1.4 3.5 ± 1.4 3.8 ± 1.8 1.19 (1,50) .280 
PLA     3.6 ± 2.0 3.2 ± 1.4 3.4 ± 1.5 3.1 ± 1.2 0.75 (1,50) .525 
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Table 3. sLac and sLys before, during and at end of 12 weeks of bovine colostrum (COL)/placebo (PLA) supplementation. Main effect 823 
of time indicated by * p <.05.  Post hoc analysis could not reveal any significant differences between timepoints for sLac concentration. 824 
There was a significant increase in sLac secretion rate (at 8 and 12 weeks) and sLys secretion rate (at 8 weeks) from baseline (p 825 
<.05). Values are mean ± SD. 826 
 827 
 828 
 829 
 830 
 831 
 832 
 833 
 834 
 835 
 836 
 837 
 838 
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 839 
 840 
Immune measure Group Baseline 4 weeks 8 weeks 12 weeks     F (df) P time                  F (df) P trial 
F (df) P  interaction 
sLac concentration  
(mgL-1) 
COL 3.3 ± 0.8 3.7 ± 0.8 3.7 ± 0.8 3.8 ± 0.8 3.02 (1,44) .032*            0.63 (1,44) .431 
PLA 3.8 ± 1.2 3.8 ± 1.0 4.0 ± 1.0 3.8 ± 1.0 1.58 (1,44) .198 
sLac secretion rate  
(gmin-1) 
COL 1.6 ± 1.0 1.9 ± 1.2 2.0 ± 0.9 2.1 ± 0.8  6.29 (1,44) .001*          0.84 (1,44) .365   
PLA 1.9 ± 1.0 2.1 ± 1.2 2.3 ± 1.4 2.3 ± 1.3 0.29 (1,44) .829 
sLac:osmolality  
(mgmOsmol-1) 
COL 0.05 ± 0.02 0.06 ± 0.02 0.06 ± 0.02 0.06 ± 0.02  2.04 (1,44) .111           0.36 (1,44) .549 
PLA 0.06 ± 0.02 0.06 ± 0.02 0.06 ± 0.02 0.06 ± 0.02 1.29 (1,44) .282 
sLys concentration 
 (mgL-1) 
COL 21.5 ± 13.3 23.0 ± 13.5 22.3 ± 12.6 20.1 ± 12.8 0.57 (1,44) .636          0.04 (1,44) .837 
PLA 22.0 ± 14.6 20.1 ± 12.1 21.3 ± 11.5 21.1 ± 12.1 1.25 (1,44) .295 
sLys secretion rate  
(gmin-1) 
COL 9.9 ± 8.3 10.5 ± 6.5 11.4 ± 8.4   10.0 ± 5.1 2.91 (1,44) .037*        0.09 (1,44) .764 
PLA 10.8 ± 8.8 10.7 ± 8.4 11.7 ± 7.4    11.6 ± 8.8 0.58 (1,44) .627 
sLys:osmolality  
(mgmOsmol-1) 
COL 0.34 ± 0.23 0.36 ± 0.25 0.33 ± 0.17 0.30 ± 0.18   0.59 (1,44) .622           0.01 (1,44) .941 
PLA 0.33 ± 0.22 0.31 ± 0.20 0.33 ± 0.19 0.33 ± 0.19 0.95 (1,44) .420 
44 
 
Table 4. Tentative identifications of metabolites which may be responsible for the 841 
separation between the 2 timepoints visible in DF1 of Figure 3.  For some of the whole 842 
number molecular weight bins there are multiple tentative IDs which may or may not 843 
contribute to the DF1 loading. Change from the baseline and subsequent ANOVA P 844 
values are detailed alongside the tentative IDs. 845 
MW Tentative ID 
Change from 
Baseline 
F (df) P  
108 Cresol Decrease 5.31 (3,100) .002 
154 
Gentisic acid 
Decrease 84.70 (3,100) < .001 
2-Pyrocatechuic acid 
Protocatechuic acid 
Hydroxytyrosol 
155 L-Histidine Increase 94.18 (3,100) <.001 
157 Unknown Increase 53.65 (3,100) <.001 
168 
Uric acid 
Decrease 16.11 (3,100) <.001 
Homogentisic acid 
3-Hydroxymandelic acid 
3,4-Dihydroxybenzeneacetic 
acid 
Pyridoxamine 
169 
Norepinephrine 
Increase 11.13 (3,100) <.001 
Pyridoxine 
3-Methylhistidine 
D-Glyceraldehyde 3-phosphate 
Dihydroxyacetone phosphate 
170 
Gallic acid 
Increase 36.68 (3,100) <.001 3,4-Dihydroxyphenylglycol 
cis-4-Decenoic acid 
172 
Glycerol 3-phosphate 
Decrease 6.57 (3,100) <.001 
Glycylproline 
173 
2-Oxoarginine 
Increase 12.43 (3,100) <.001 
Pyrophosphate 
174 
Dehydroascorbic acid 
Increase 68.56 (3,100) <.001 
Suberic acid 
N-Acetylornithine 
L-Arginine 
186 
2-Phosphoglyceric acid 
Decrease 17.48 (3,100) <.001 
3-Phosphoglyceric acid 
285 Unknown Increase 6.19 (3,100) <.001 
325 
10-Nitrolinoleic acid 
Decrease 11.86 (3,100) <.001 
N-Oleoylethanolamine 
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